Melbourne, Australia, 13 June 2022: Certa Therapeutics, a biotechnology company focused on improving lives by developing innovative precision treatments for inflammatory and fibrotic diseases, announced today that its Chief Executive Officer, Professor Darren Kelly, will be attending the 2022 Biotechnology Innovation Organisation International Convention (BIO).
After the past two conventions were held in a virtual format due to Covid-19, this year’s conference will be held between 13–16 2022June in San Diego, California.
Certa Therapeutics is a biotechnology company focused on improving lives by developing innovative precision treatments for inflammatory and fibrosis diseases.
During the convention, the Certa team will highlight their innovative scientific advancements including their ongoing clinical development program for the lead candidate FT011 and the mechanism of action for the drugs in the treatment of inflammatory and fibrotic diseases.
“We’re excited to attend the first in-person BIO since 2019. It’s a great opportunity for us to meet with industry leaders and discuss the scientific advancements in our program for inflammatory and fibrotic diseases,” says Professor Darren Kelly, CEO of Certa Therapeutics.
The BIO 2022 convention is attracting more than 3,000 international and domestic companies from across the biotech industry, as well as many global industry leaders and top research scholars.